11 results about "Bacterial polysaccharide" patented technology

The invention relates to a porcine bacterial polysaccharide-viral protein conjugate vaccine as well as a preparation method and application thereof, and belongs to the technical field of animal vaccines. The vaccine takes porcine bacterial polysaccharide and virus protein as raw materials, and a polysaccharide-virus protein conjugate is formed through coupling of a biotin-avidin system; wherein the virus protein is selected from one of classical swine fever virus E2 protein, porcine circovirus type 2 Cap protein, porcine pseudorabies virus gD protein and the like, and the porcine bacterial polysaccharide is selected from one of streptococcus suis capsular polysaccharide, porcine pasteurella multocida capsular polysaccharide and the like. The vaccine can simultaneously induce an organism to generate a high-level IgG antibody aiming at porcine bacterium capsular polysaccharide and virus protein, so that synergistic immune protection on porcine bacterium and virus infection is realized, and a broad-spectrum cross immune effect is achieved.

The present disclosure relates to alternative, cost effective, rapid and simple methods for bacterial capsular polysaccharide (CPS) manufacturing resulting in 1) simultaneous sizing and purification of CPS 2) high CPS yield, 3) improved CPS purity and removal of protein and nucleic acid contaminants, 4) CPS with preserved epitopic conformation and 5) stable and immunogenic polysaccharide-protein conjugate vaccines comprising of said size reduced and purified CPS The method particularly comprises subjecting crude / native bacterial polysaccharide to an oxidizing agent to obtain high purity, high yield and structurally intact CPS having optimal molecular size and other desirable CPS attributes. The method is amenable for commercial scale manufacturing of polysaccharide-protein conjugate vaccines.

The present disclosure relates to a method for obtaining purified bacterial polysaccharides. The method comprises simultaneous removal of impurities as well as sizing of bacterial polysaccharides using an acid instead of conventional mechanical sizing methods. The method is simple, rapid and cost effective. The method results in high polysaccharide recovery and low impurity content. The purified polysaccharide obtained by the method of the present disclosure may be used for large scale production of polysaccharide-protein conjugate vaccines.

The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

Provided are vaccine compositions comprising a liposome, a bacterial polysaccharide antigen, and an invariant natural killer T (iNKT) cell agonist, methods of treating or preventing a bacterial infection using the compositions, and nasal spray devices comprising them.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins, which may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. Suitable carriers may include but are not limited to Haemophilus influenzae protein D (PD), Neisseria meningitidis porin protein (PorA), Corynebacterium diphtheriae toxin (CRM 197), Clostridium tetani toxin (TT), and Escherichia coli maltose binding protein, and variants thereof.

This invention relates to the field of veterinary drug product technology, and more specifically, to a veterinary vaccine enhancer and its preparation and application. The veterinary vaccine enhancer comprises, by weight, the following components: 20-30 parts bacterial polysaccharide, 20-30 parts astragalus polysaccharide, 10-20 parts saponin, 4-12 parts vitamin B and C compound additive, and 1-5 parts polyethylene glycol 1000. The vaccine prepared using this invention is stable, safe, has high antibody titers, rapid antibody production, and long-lasting immunity, exhibiting excellent overall performance. The preparation method of the veterinary vaccine enhancer of this invention is simple, convenient, and low-cost, suitable for large-scale production and widespread application.

The application provides a method for efficiently and rapidly removing Microcystis aeruginosa and CTAB by using bacterial polysaccharide, comprising the following steps: (1) mixing CTAB with a water sample to be treated to obtain a mixed solution, and culturing together, wherein the water sample to be treated contains Microcystis aeruginosa; (2) adding bacterial polysaccharide into the mixed solution of Microcystis aeruginosa and CTAB obtained in the step (1), and mixing uniformly to flocculate the Microcystis aeruginosa and CTAB; and (3) separating the flocculation of the bacterial polysaccharide, Microcystis aeruginosa and CTAB obtained in the step (2) through a 30-mesh sieve. The positively charged CTAB is adsorbed on the negatively charged Microcystis aeruginosa and bacterial polysaccharide, and the CTAB is removed by collecting the microalgae flocculation. The Microcystis aeruginosa and CTAB in water can be removed by the method.

The invention provides a method for detecting the size of polysaccharide molecules of a multivalent bacterial vaccine, which is characterized by comprising the following steps in sequence: 1) providing a mixed solution of bacterial polysaccharides containing various serotypes; 2) performing a gel filtration method on the mixed solution to obtain a continuously collected multi-tube eluent; and 3) carrying out rate turbidimetry on the multi-tube eluent to obtain the amount of each type of bacterial polysaccharide in each tube, and respectively obtaining the KD value of each type of bacterial polysaccharide according to the amount of each type of bacterial polysaccharide. According to the method, the detection efficiency of the molecular size of the bacterial polysaccharide is greatly improved, the operation is simple, sensitive and accurate, the automation degree is high, and a guarantee is provided for research, development, production and quality control of bacterial vaccines.

The invention discloses a bacterial polysaccharide hydrolysis method and application thereof, and belongs to the field of vaccine preparation. According to the bacterial polysaccharide hydrolysis method, polysaccharide is hydrolyzed to generate monosaccharide in a microwave heating mode, the hydrolysis time can be saved, the hydrolysis efficiency can be improved, further degradation of the hydrolyzed monosaccharide is effectively reduced by adjusting and controlling the reaction power, the reaction temperature, the reaction time and the like, and the yield is improved. Therefore, the accuracy of identifying the polysaccharide structure is improved; the hydrolysis method disclosed by the invention can be applied to streptococcus pneumoniae polysaccharide, and monosaccharide hexosamine generated after streptococcus pneumoniae glycosaminoglycan is hydrolyzed is subjected to specific determination, so that the accuracy of glycosaminoglycan content determination is improved. The method disclosed by the invention is suitable for a vaccine preparation process and a vaccine quality control process, and has important significance for improving the quality controllability of a vaccine product.